Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Intellia Therapeutics US45826J1051

Intellia Therapeutics finds itself in a challenging phase as regulatory delays for a key drug candidate trigger a wave of downgrades from Wall Street analysts. The central question for investors is whether the company’s substantial cash reserves provide enough runway to resolve regulatory concerns and restore confidence.

Despite the negative sentiment, Intellia’s latest operational update revealed underlying strength. For the third quarter of 2025, the company reported a narrower-than-expected loss per share of -$0.92. Revenue showed significant growth, climbing over 50% year-over-year to reach $13.78 million. Perhaps most critically, the firm’s liquidity position remains robust, with nearly $670 million on hand, providing funding into mid-2027.